Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioCorRxBICX 29 3-Year EBITDA Growth Rate is 31.70% as of Jun. 2026, which is 3422% above its 10-year median of 0.90. GuruFocus rates BICX with a GF Score™ of 29/100 and a GF Value™ of $2.12 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 524 Healthcare Providers & Services companies, BioCorRx ranks better than 79.01% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 31.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 22.80% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 22.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of BioCorRx was 59.60% per year. The lowest was -776.80% per year. And the median was 0.90% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
BioCorRx 3-Year EBITDA Growth Rate Related Terms
BICX vs VLXC, XCRT, RHEP: 3-Year EBITDA Growth Rate Comparison
For the Medical Care Facilities subindustry, BioCorRx's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioCorRx 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, BioCorRx's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where BioCorRx's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 31.70% mean?
BioCorRx (BICX) has a 3-Year EBITDA Growth Rate of 31.70% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for BioCorRx and its competitors. This is 3422% above median its historical median of 0.90. According to the industry distribution chart, BioCorRx ranks #110 out of 524 companies in the Healthcare Providers & Services industry, placing it in the top 21%.
Is BioCorRx's 3-Year EBITDA Growth Rate too high?
BioCorRx's current 3-Year EBITDA Growth Rate of 31.70% is 3422% above median its 10-year median of 0.90. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 9.90. BioCorRx's value of 31.70% is 220.2% above this industry median. Based on the distribution chart, BioCorRx ranks #110 out of 524 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, BioCorRx has a GF Score™ of 29/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioCorRx's 3-Year EBITDA Growth Rate compare to VLXC and XCRT?
According to the Healthcare Providers & Services industry distribution chart, BioCorRx ranks #110 out of 524 companies for 3-Year EBITDA Growth Rate. This places BioCorRx in the top 21% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 9.90. BioCorRx's value of 31.70% is 220.2% above this benchmark. While the company's 10-year median is 0.90 vs. the industry median of 9.90, BioCorRx has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 9.90, based on 524 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioCorRx's current 3-Year EBITDA Growth Rate of 31.70% is 220.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for BioCorRx and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 9.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioCorRx's current 3-Year EBITDA Growth Rate is 31.70%, which is 3422% above median its own 10-year median of 0.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioCorRx stock overvalued right now?
Based on GuruFocus' analysis, BioCorRx (BICX) is currently considered Possible Value Trap. The stock's GF Value™ is $2.12, compared to a current price of $0.21 — trading 90.1% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 31.70%, which is 3422% above median its 10-year median of 0.90 and 220.2% above the Healthcare Providers & Services industry median of 9.90. BioCorRx's overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For BioCorRx (BICX), the current 3-Year EBITDA Growth Rate is 31.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioCorRx (BICX) Overvalued in 2026?
Based on GuruFocus' analysis, BioCorRx stock appears to be undervalued.
The current stock price of $0.21 is trading 90.1% below its estimated GF Value™ of $2.12.
GuruFocus considers BioCorRx to be Possible Value Trap.
Key valuation signals for BICX:
3-Year EBITDA Growth Rate: 31.70% (3422% above median its 10-year median of 0.90)
GF Value™: $2.12 vs. price of $0.21 (90.1% below fair value)
Industry Position: 220.2% above the Healthcare Providers & Services median (#110 of 524)
No single metric tells the full story. See the BICX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioCorRx Inc through its subsidiaries, develops and provides addiction treatment solutions, offering an approach to the treatment of substance use and other related disorders. The company makes the Beat Addiction Recovery Program and UnCraveRx Weight Loss Management Program available to healthcare providers to utilize when the healthcare provider determines it is medically appropriate and indicated for their patients. Its products include BICX102 and BICX104. It operates in a single segment.
29GF Score
Get the complete analysis for BICX
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BICX has been successfully added to your 
